News

Researchers refine in vitro test that will reduce the risk of “first in humans” drug trials

BMJ 2008; 337 doi: 10.1136/bmj.a3061 (Published 18 December 2008)
Cite this as: BMJ 2008;337:a3061

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Susan Mayor
  1. 1London

    UK researchers investigating what went wrong in the drug trial with the immunomodulator TGN1412 in 2006, in which six healthy volunteers became critically ill, have developed an in vitro test that could have predicted the drug’s serious side effects before it was tested in humans.

    The six men had catastrophic multiorgan failure when they took part in a “first in humans” trial of TGN1412—a monoclonal superagonist of the CD28 T cell surface receptor, which was being tested for use in autoimmune conditions. The drug triggered a systemic inflammatory response with rapid induction of proinflammatory cytokines; this caused a life threatening “cytokine storm,” which had not been predicted from preclinical testing (BMJ 2006;333:570; 10.1136/bmj.333.7568.570).

    The UK Medicine and Healthcare Products Regulatory Agency (MHRA) commissioned the government funded National Institute …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular